Abstract
We designed a multicenter Phase II trial to prospectively evaluate the efficacy and safety of the combination of rituximab with the DHAP regimen (dexamethasone, high-dose cytarabine, cisplatin) in patients who relapsed after or were resistant to a CHOP-like regimen. A total of 53 patients with relapsed or resistant aggressive B-cell NHL were analyzed. The overall response rate was 62.3 percent. With a median follow-up of 24.9 months, median overall and progression-free survivals were 8.5 and 6.7 months, respectively. Immunochemotherapy with rituximab and DHAP proved to be feasible and effective in this patient population.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Cytarabine / administration & dosage
-
Dexamethasone / administration & dosage
-
Disease-Free Survival
-
Dose-Response Relationship, Drug
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Lymphoma, B-Cell / drug therapy
-
Lymphoma, B-Cell / pathology
-
Lymphoma, Follicular / drug therapy
-
Lymphoma, Follicular / pathology
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / pathology
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / pathology
-
Prospective Studies
-
Rituximab
-
Salvage Therapy*
-
Survival Rate
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Cytarabine
-
Rituximab
-
Dexamethasone
-
Cisplatin